S Stoĭnov

1.5k total citations · 1 hit paper
8 papers, 1.2k citations indexed

About

S Stoĭnov is a scholar working on Genetics, Hematology and Surgery. According to data from OpenAlex, S Stoĭnov has authored 8 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Genetics, 3 papers in Hematology and 2 papers in Surgery. Recurrent topics in S Stoĭnov's work include Inflammatory Bowel Disease (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Iron Metabolism and Disorders (2 papers). S Stoĭnov is often cited by papers focused on Inflammatory Bowel Disease (3 papers), Hemoglobinopathies and Related Disorders (2 papers) and Iron Metabolism and Disorders (2 papers). S Stoĭnov collaborates with scholars based in Belgium, United States and Russia. S Stoĭnov's co-authors include Ralph Bloomfield, Stefan Schreiber, Brian G. Feagan, David Mason, William J. Sandborn, Paul Rutgeerts, Geert D’Haens, Stefanie Kulnigg, Waldemar Karnafel and Christoph Gasché and has published in prestigious journals such as New England Journal of Medicine, Gastroenterology and Journal of Hepatology.

In The Last Decade

S Stoĭnov

7 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Certolizumab Pegol for the Treatment of Crohn's Disease

2007 863 citations William J. Sandborn, Brian G. Feagan et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by S Stoĭnov

Since Specialization

Citations

This map shows the geographic impact of S Stoĭnov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S Stoĭnov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S Stoĭnov more than expected).

Fields of papers citing papers by S Stoĭnov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S Stoĭnov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S Stoĭnov. The network helps show where S Stoĭnov may publish in the future.

Co-authorship network of co-authors of S Stoĭnov

This figure shows the co-authorship network connecting the top 25 collaborators of S Stoĭnov. A scholar is included among the top collaborators of S Stoĭnov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S Stoĭnov. S Stoĭnov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

#	Work	Indexed citations
1	446 TIMING AND FREQUENCY OF DEPRESSION DURING HCV-TREATMENT WITH CONTROLLED-RELEASE-IFNA2B (CR2B) VS. PEGYLATED-IFNA2B (PEG2B): RESULTS FROM SELECT-2, A RANDOMIZED-OPEN-LABEL-72-WEEK-COMPARISON IN 116 TREATMENT-NAIVE PATIENTS WITH GENOTYPE-1 HCV 2011 ·Journal of Hepatology ·W.A. Long, Zobair M. Younossi, E. Läwitz, (unknown), (unknown), К. Tchernev, (unknown), Reem Ghalib, S Stoĭnov, R. Balabanska, P. Mehra, (unknown)	2
2	Efficacy, Safety and Tolerability of Vidofludimus in Patients With Inflammatory Bowel Disease: The ENTRANCE Study 2011 ·Gastroenterology ·Klaus Herrlinger, Mircea Diculescu, Klaus Fellermann, Heinz Hartmann, Stefanie Howaldt, (unknown), (unknown), Wolfgang Reindl, Jan‐Michel Otte, S Stoĭnov, Ulrike Strauch, Andreas Sturm, (unknown), Aldo Ammendola, Bruno Dietrich, Bernd Hentsch, Eduard F. Stange	8
3	A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT^®) Randomized Controlled Trial 2008 ·The American Journal of Gastroenterology ·Stefanie Kulnigg, S Stoĭnov, (unknown), (unknown), Waldemar Karnafel, (unknown), Alicia M. Sambuelli, Geert D’Haens, Christoph Gasché	290
4	Certolizumab Pegol for the Treatment of Crohn's Disease breakdown → 2007 ·New England Journal of Medicine ·William J. Sandborn, Brian G. Feagan, S Stoĭnov, (unknown), Paul Rutgeerts, David Mason, Ralph Bloomfield, Stefan Schreiber	863
5	A novel intravenous iron formulation for treatment of anemia in IBD: The ferinject randomized, controlled trial 2007 ·Zeitschrift für Gastroenterologie ·Stefanie Kulnigg, (unknown), S Stoĭnov, В. И. Симаненков, E. Levchenko, Waldemar Karnafel, (unknown), Geert D’Haens, Christoph Gasché	6
6	[Polyposis of the colon and cancer]. 2004 ·PubMed ·(unknown), S Stoĭnov, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	2
7	Fontolizumab (Huzaf), a humanized anti-IFN-gamma antibody, has clinical activity and excellent tolerability in moderate to severe Crohn’s disease 2004 ·Gastroenterology ·Daniël W. Hommes, (unknown), S Stoĭnov, Davor Štimac, Boris Vucelić, János Lonovics, (unknown), Geert D’Haens, Gert Van Assche, Tillman Pearce	30
8	[Classifications and prognosis of hepatocellular carcinoma]. 2002 ·PubMed ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), S Stoĭnov	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact